Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - néoplasmes du sein - en endocrinologie, des anti-oestrogènes - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. en pré - ou en périménopause les femmes, la combinaison de traitement avec palbociclib doit être combiné avec un lutéinisante hormone releasing hormone (lh-rh) agoniste.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozine propanediol monohydraté - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - les médicaments utilisés dans le diabète - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. en outre, à d'autres médicaments pour le traitement du diabète de type 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 et 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab  - la metformine chlorhydrate, chlorhydrate de saxagliptine - diabète sucré, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - komboglyze est indiqué comme adjuvant au régime et pour améliorer le contrôle glycémique chez les patients adultes âgés de 18 ans et plus atteints de diabète de type 2 insuffisamment contrôlés sur leurs doses maximales tolérées de metformine seule ou ceux qui sont déjà traités par la combinaison de saxagliptine et metformine sous forme de comprimés séparés. komboglyze est également indiqué en association avec l'insuline (je. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice pour améliorer le contrôle glycémique chez les patients adultes âgés de 18 ans et plus, atteints de diabète de type 2 mellitus de diabète lorsque l'insuline et la metformine seule ne donnent pas suffisamment de contrôle glycémique.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - olaparib - néoplasmes ovariens - agents antinéoplasiques - de l'ovaire cancerlynparza est indiqué en monothérapie pour le:le traitement d'entretien chez les patients adultes atteints avancé (stades figo iii et iv) les gènes brca1/2-muté (de la lignée germinale et/ou somatiques) de haute qualité épithélial de l'ovaire, des trompes de fallope ou péritonéal primitif du cancer et qui sont en réponse (complète ou partielle) à la suite de l'achèvement de la première ligne de chimiothérapie à base de platine. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 et 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. les patients doivent avoir été précédemment traités avec une anthracycline et un taxane dans le (néo)adjuvante ou métastatique à moins que les patients n'étaient pas adaptés à ces traitements (voir la section 5. les patients ayant des récepteurs hormonaux (rh)-cancer du sein devraient également avoir progressé sur l'avant ou après traitement endocrinien, ou être considéré comme impropre à la thérapie endocrinienne. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinome, poumon non à petites cellules - d'autres agents antinéoplasiques, les inhibiteurs de protéines kinases - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - la saxagliptine - diabète sucré, type 2 - les médicaments utilisés dans le diabète - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - asthme - les médicaments pour les maladies respiratoires obstructives, - fasenra est indiqué comme un complément sur le traitement d'entretien chez les patients adultes atteints de graves éosinophiles de l'asthme insuffisamment contrôlé en dépit d'une forte dose de corticostéroïdes inhalés plus longue durée d'action des agonistes ß.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - de sodium de zirconium cyclosilicate - hyperkaliémie - tous les autres produits thérapeutiques - lokelma est indiqué pour le traitement de l'hyperkaliémie chez les patients adultes.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucémie, lymphocytaire, chronique, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.